[Edaily Reporter Park Jung-Soo ] Pangen Biotech Inc.(222110)announced on the 22nd that it has been awarded a research contract worth 2.74545 billion won from the National Institute of Health under the Korea Disease Control and Prevention Agency (KDCA) for the “Optimization and Evaluation of a Non-clinical Sample Production System for Antibodies to Treat Severe Fever with Thrombocytopenia Syndrome (SFTS).” The contract amount represents 20.46% of last year’s revenue, and the contract period runs through December 31, 2028.